Biomedical Engineering Reference
In-Depth Information
52. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. (1998) IL-
10 reduces rat brain injury following focal stroke. Neurosci.
Lett. 251, 189-192.
53. Plunkett JA, Yu CG, Easton JM, Bethea JR, Yezierski RP.
(2001) Effects of interleukin-10 (IL-10) on pain behavior and
gene expression following excitotoxic spinal cord injury in
the rat. Exp. Neurol. 168, 144-154.
54. Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann
M, (2004) Erythropoietin: novel approaches to neuroprotec-
tion in human brain disease. Metab. Brain Dis. 19, 195-206.
55. Juul S. (2004) Recombinant erythropoietin as a neuroprotec-
tive treatment: in vitro and in vivo models. Clin. Perinatol. 31,
129-142.
56. Brines M, Cerami A. (2005) Emerging biological roles for
erythropoietin in the nervous system. Nat. Rev. Neurosci. 6,
484-494.
57. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines
ML, et al.(2002) Erythropoietin exerts an anti-inflammatory
effect on the CNS in a model of experimental autoimmune
encephalomyelitis. Brain Res. 952, 128-134.
58. Li W, Maeda Y, Yuan RR, Elkabes S, Cook S, Dowling P.
(2004) Beneficial effect of erythropoietin on experimental
allergic encephalomyelitis. Ann. Neurol. 56, 767-777.
59. Zhang J, Li Y, Cui Y, Chen J, Lu M, Elias SB, et al. (2005)
Erythropoietin treatment improves neurological functional
recovery in EAE mice. Brain Res. 1034, 34-39.
60. Rosenberg GA. (2002) Matrix metalloproteinases and neuro-
inflammation in multiple sclerosis. Neuroscientist 8, 586-
595.
61. Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu
Z, et al. (2006) Matrix metalloproteinase-9 (MMP-9) and
tissue inhibitor of matrix metalloproteinase (TIMP-1) in
patients with relapsing-remitting multiple sclerosis treated
with interferon beta. Clin. Neurol. Neurosurg. 108, 124-128.
62. Yong VW, Zabad RK, Agrawal S, Goncalves Dasilva A, Metz
LM. (2007) Elevation of matrix metalloproteinases (MMPs)
in multiple sclerosis and impact of immunomodulators. J.
Neurol. Sci. 259, 79-84.
63. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender
N, Stiefel M, et al. (2007) Exploring recombinant human
erythropoietin in chronic progressive multiple sclerosis.
Brain 130, 2577-2588.
64. Schluesener HJ, Lider O. (1989) Transforming growth factors
beta 1 and beta 2: cytokines with identical immuno-
suppressive effects and a potential role in the regulation of
autoimmune T cell function. J. Neuroimmunol. 24, 249-258.
65. Johns LD, Flanders KC, Ranges GE, Sriram S. (1991)
Successful treatment of experimental allergic encephalomye-
litis with transforming growth factor-beta 1. J. Immunol. 147,
1792-1796.
66. McCartney-Francis NL, Frazier-Jessen M, Wahl SM.
(1998) TGF-beta: a balancing act. Int. Rev. Immunol. 16,
553-580.
67. van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ,
Plater-Zyberk C, Vervoordeldonk MJ. (2004) Treatment with
recombinant interferon-beta reduces inflammation and slows
cartilage destruction in the collagen-induced arthritis model
of rheumatoid arthritis. Arthritis Res. Ther. 6, R239-249.
68. Schuppan D, Freitag T. (2004) Fistulising Crohn's disease:
MMPs gone awry. Gut 53, 622-624.
69. von Lampe B, Barthel B, Coupland SE, Riecken EO, Rose-
wicz S. (2000) Differential expression of matrix metallopro-
teinases and their tissue inhibitors in colon mucosa of patients
with inflammatory bowel disease. Gut 47, 63-73.
70. Shah PK, Galis ZS. (2001) Matrix metalloproteinase hypoth-
esis of plaque rupture: players keep piling up but questions
remain. Circulation 104, 1878-1880.
71. Pinderski Oslund LJ, Hedrick CC, Olvera T, Hagenbaugh A,
Territo M, Berliner JA, et al. (1999) Interleukin-10 blocks
atherosclerotic events in vitro and in vivo. Arterioscler.
Thromb. Vasc. Biol. 19, 2847-2853.
72. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. (2001)
Serum levels of the antiinflammatory cytokine interleukin-10
are decreased in patients with unstable angina. Circulation
104, 746-749.
73. Rennick DM, Fort MM. (2000) Lessons from genetically
engineered animal models. XII. IL-10-deficient (IL-10(-/-)
mice and intestinal inflammation. Am. J. Physiol. Gastro-
intest. Liver Physiol. 278, G829-833.
74. Li MC, He SH. (2004) IL-10 and its related cytokines for
treatment of inflammatory bowel disease. World J. Gastro-
enterol. 10, 620-625.
75. Tilg H, Ulmer H, Kaser A, Weiss G. (2002) Role of IL-10 for
induction of anemia during inflammation. J. Immunol. 169,
2204-2209.
76. Tilg H, van Montfrans C, van den Ende A, Kaser A, van
Deventer SJ, Schreiber S, et al. (2002) Treatment of Crohns
disease with recombinant human interleukin 10 induces
the proinflammatory cytokine interferon gamma. Gut 50,
191-195.
77. Paul WE. (1991) Interleukin-4: a prototypic immuno-
regulatory lymphokine. Blood 77, 1859-1870.
78. George J, Mulkins M, Shaish A, Casey S, Schatzman R, Sigal
E, et al. (2000) Interleukin (IL)-4 deficiency does not influ-
ence fatty streak formation in C57BL/6 mice. Atherosclerosis
153, 403-411.
79. Huber SA, Sakkinen P, David C, Newell MK, Tracy RP.
(2001) T helper-cell phenotype regulates atherosclerosis in
mice under conditions of mild hypercholesterolemia. Circu-
lation 103, 2610-2616.
80. Khew-Goodall Y, Wadham C, Stein BN, Gamble JR, Vadas
MA. (1999) Stat6 activation is essential for interleukin-4
induction of P-selectin transcription in human umbilical
vein endothelial cells. Arterioscler. Thromb. Vasc. Biol.
19, 1421-1429.
81. Cornicelli JA, Butteiger D, Rateri DL, Welch K, Daugherty
A. (2000) Interleukin-4 augments acetylated LDL-induced
cholesterol esterification in macrophages. J. Lipid Res. 41,
376-383.
82. Vessillier S, Adams G, Montero-Melendez T, Jones R,
Seed M, Perretti M, Chernajovsky Y. (2012) Molecular
engineering
of
short
half-life
small
peptides
(VIP,
Search WWH ::




Custom Search